RECRUITING

Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.

Official Title

Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge

Quick Facts

Study Start:2025-03-09
Study Completion:2026-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06852950

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC
  2. * Able to give informed consent
  3. * Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge
  4. * POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL
  5. * Need glucose readings greater than or equal to one time per day
  6. * Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone
  1. * Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months
  2. * Does not have smartphone compatible with Libre 3 App or Dexcom G7 App
  3. * Received chemotherapy during current hospitalization
  4. * Planning on major surgery within 10-15 days
  5. * Hemodialysis or peritoneal dialysis
  6. * Requiring vasopressors, intubation, sedation, or admission to an intensive care unit
  7. * Vitamin C use of more than 500 milligrams per day
  8. * Hydroxyurea use
  9. * Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours
  10. * Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion
  11. * Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state
  12. * Skin allergy to adhesives

Contacts and Locations

Study Contact

Angel Morvant, MD
CONTACT
615-343-8332
angel.morvant@vumc.org

Study Locations (Sites)

Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States

Collaborators and Investigators

Sponsor: Vanderbilt University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-09
Study Completion Date2026-01

Study Record Updates

Study Start Date2025-03-09
Study Completion Date2026-01

Terms related to this study

Additional Relevant MeSH Terms

  • Type 2 Diabetes Mellitus (T2DM)
  • Type 1 Diabetes Mellitus (T1DM)
  • Hyperglycemia